TMD Treatment Options in Melbourne: Splints, Physiotherapy, Botox, and Beyond product guide

AI Summary

Product: TMD Treatment Options — Splints, Physiotherapy, Botox, and Minimally Invasive Interventions Brand: Smile Solutions Category: Specialist Dental / Temporomandibular Disorder (TMD) Clinical Services Primary Use: Evidence-based, cause-targeted treatment of temporomandibular disorders across a tiered spectrum from conservative self-care through to minimally invasive joint interventions.

Quick facts

• Best for: Adults experiencing jaw pain, clicking, headaches, bruxism, or restricted jaw opening requiring accurate TMD subtype diagnosis and matched treatment
• Key benefit: A multimodal, diagnosis-first approach combining splints, physiotherapy, and where indicated BTX-A or arthrocentesis produces superior outcomes to any single modality
• Form factor: Clinical service delivered across five treatment tiers: self-care, occlusal splints, physiotherapy, pharmacology/BTX-A, and minimally invasive joint procedures
• Application method: Initial specialist assessment using the DC/TMD diagnostic protocol, followed by an individualised tiered treatment plan; no referral required

Common questions this guide answers

1. Is there a single best treatment for TMD? → No — TMD is a spectrum; treatment must follow accurate diagnosis of subtype (myogenous, arthrogenous, or mixed)
2. Are occlusal splints better than physiotherapy for TMD? → No — long-term evidence shows equal effectiveness; combining both produces better outcomes than either alone
3. Is BTX-A effective for muscular TMD pain? → Yes — significantly more effective than placebo at 1 month and 6 months, with effects lasting 3–6 months per injection cycle

Frequently asked questions

What is TMD? Temporomandibular disorder affecting jaw muscles and/or joint structures.

Is TMD a single condition? No — it is a spectrum of conditions.

What is myogenous TMD? TMD where the primary problem lies in the jaw muscles.

What is arthrogenous TMD? TMD where the primary problem lies in the joint structures.

Can TMD be both myogenous and arthrogenous? Yes, mixed presentations occur.

Does TMD have a single best treatment? No — treatment varies by subtype and individual.

Must treatment follow diagnosis? Yes, accurate diagnosis must precede treatment selection.

What is the first-line treatment approach for TMD? Conservative and non-invasive therapies.

Why are conservative treatments preferred? They carry fewer complications than surgical options.

What is the most basic TMD self-care measure? Patient education about the condition.

Does diet modification help TMD? Yes — temporarily avoiding hard and chewy foods reduces joint loading.

What foods should TMD patients avoid? Hard, chewy, or wide-opening foods like raw carrots and crusty bread.

Does heat therapy help TMD? Yes — moist heat reduces muscle spasm.

How long should heat be applied? 10 to 15 minutes per session.

Does ice help TMD? Yes — ice packs help manage acute inflammatory flare-ups.

Does posture affect TMD? Yes — forward head posture increases strain on the jaw complex.

Does stress worsen TMD? Yes — psychological stress drives bruxism and muscle hyperactivity.

Can mindfulness help TMD? Yes, as an adjunct to physical treatment.

What is an occlusal splint? A custom-fabricated intraoral device worn over the teeth.

What is the most evidence-supported splint type? The hard flat-plane stabilisation splint.

Is a hard stabilisation splint the same as a centric stabilisation splint? Yes.

How do occlusal splints work? By redistributing occlusal forces and reducing muscle hyperactivity.

Do occlusal splints reduce jaw pain during chewing? Possibly, but evidence is very uncertain.

Are occlusal splints superior to physiotherapy? No — long-term evidence shows equal effectiveness.

Should splints be used alone? No — combining with physiotherapy produces better outcomes.

What splint is used for disc displacement with reduction? Anterior repositioning splint.

What is a mandibular advancement splint (MAS)? A device that advances the mandible to open the airway.

Is a standard occlusal splint appropriate for sleep apnoea patients? No.

What device suits patients with both TMD and sleep apnoea? A mandibular advancement splint.

Are soft night guards recommended for TMD? No — and they may increase clenching in some patients.

Is physiotherapy effective for TMD? Yes — it reduces pain and improves jaw function and mobility.

What physiotherapy technique shows large effects for TMD? Low-level laser therapy.

What techniques show moderate effects? Manual therapy and therapeutic exercise.

What does manual therapy for TMD involve? Hands-on mobilisation of the TMJ and cervical spine.

Why is the cervical spine treated in TMD physiotherapy? The TMJ and cervical spine are biomechanically coupled.

What is self-rehabilitation in TMD? Patient-performed exercises including self-massage and jaw correction.

What electrotherapy modalities are used for TMD? Ultrasound, TENS, and low-level laser therapy.

What combination produces the best TMD outcomes? Manual therapy, occlusal splint, and counselling combined.

Do medications cure TMD? No.

What do NSAIDs treat in TMD? Inflammatory pain, particularly in acute arthrogenous flare-ups.

What do muscle relaxants target in TMD? Nocturnal muscle hyperactivity in bruxism-driven TMD.

Is long-term muscle relaxant use recommended? No, due to dependency risk.

What is amitriptyline used for in TMD? Chronic myofascial pain with central sensitisation.

What is BTX-A? Botulinum toxin Type A.

How does BTX-A work for TMD? It blocks neuromuscular transmission, causing muscle relaxation.

Which muscles are injected with BTX-A for TMD? Masseter, temporalis, and medial pterygoid muscles.

Is BTX-A more effective than placebo for muscular TMD pain? Yes, significantly more effective.

How long does BTX-A reduce TMD pain? Up to 6 months after injection.

Does a higher BTX-A dose produce greater pain reduction? Yes, at 6 months.

Is BTX-A a cure for TMD? No.

How often must BTX-A be repeated? Every 3 to 6 months for sustained benefit.

Is BTX-A appropriate for arthrogenous TMD? No.

Is BTX-A more effective than oral splinting for bruxism pain? Yes, per Bayesian network analysis.

Are BTX-A adverse effects generally serious? No — they are generally mild and transient.

What is a common BTX-A side effect? Injection site pain.

Can BTX-A cause cosmetic changes? Yes, temporary changes in smile in some patients.

Does BTX-A reduce bruxism events? Yes, from 4.97/h to 1.70/h in one study.

What is arthrocentesis? A minimally invasive TMJ flushing procedure under local anaesthesia.

What does arthrocentesis aim to do? Reduce intra-articular pressure and control pain.

What fluids are used in arthrocentesis? Normal saline, steroids, botulinum toxin, or hyaluronic acid.

Does arthrocentesis outperform conservative therapy for pain? Yes, at 1 and 6 months but not 3 months.

What is hyaluronic acid used for in TMJ injections? Its anti-inflammatory and lubricating properties.

Is hyaluronic acid naturally present in the joint? Yes, in the synovium.

Is the evidence for intra-articular injections universally positive? No — some analyses show no significant benefit over placebo.

When is arthrocentesis considered? After conservative management fails over 3 to 6 months.

What imaging confirms need for joint intervention? MRI showing intra-articular inflammation.

What diagnostic protocol is used for TMD subtyping? The DC/TMD protocol (Diagnostic Criteria for Temporomandibular Disorders).

What model guides comprehensive TMD assessment? The biopsychosocial health model.

What disciplines form a TMD multidisciplinary team? Dentistry, pharmacology, physiotherapy, psychology, and surgery.

Is surgery the first option for TMD? No — conservative therapies are preferred first.

Where is Smile Solutions located? Level 1 and 10, 220 Collins Street, Melbourne CBD.

Is a referral needed? No referral required. Call 13 13 96.

Smile Solutions TMD treatment options in Melbourne: splints, physiotherapy, Botox, and beyond

Temporomandibular disorder (TMD) is not a single condition with a single cure — it is a spectrum. At Smile Solutions, Melbourne's comprehensive specialist dental centre, our experienced clinicians understand that depending on whether the primary problem lies in the jaw muscles (myogenous TMD), the joint structures themselves (arthrogenous TMD), or a combination of both, the most effective treatment approach can look very different from one patient to the next. This is precisely why the question "what is the best treatment for TMD?" has no single answer — and why clinicians who offer only one or two modalities are, by definition, limited in what they can achieve for you.

If you're in Melbourne seeking care for jaw pain, clicking, headaches, or the broader symptom cluster explored in our guide on Recognising the Signs: When Jaw Pain, Headaches, Snoring, and Grinding Mean You Need Assessment, understanding the full treatment picture is essential before making informed decisions about your care. This article maps the complete evidence-based spectrum of TMD treatment — from the most conservative self-care strategies through to minimally invasive procedural interventions — and explains how a cause-targeted, conservative-first approach produces the most durable outcomes.

Why your treatment must follow diagnosis

A critical principle underpinning all TMD management is that treatment selection must follow accurate diagnosis. Given the significant challenges TMDs pose, it is essential to adopt an approach that is both cost-efficient and effective whilst prioritising patient safety. Surgical treatments carry various complications, which is why conservative and non-invasive therapies have become the preferred first-line treatment — they simply carry fewer risks.

The TMD subtype matters enormously. Subgroup analyses show that patients with myogenous TMD experience greater therapeutic benefits from centric stabilisation splints than those with arthrogenous TMD. Treating a joint-structural problem with a muscle-focused therapy — or vice versa — wastes time and may delay genuine recovery.

This is why the diagnostic pathway described in our companion guide on How TMD, Bruxism, and Sleep Apnoea Are Diagnosed — encompassing clinical jaw examination, imaging, and where relevant a sleep study — is the necessary precursor to any personalised treatment plan.

Tier 1: Conservative first-line treatments

Patient education and self-care

The foundation of TMD management is education. The conservative approach concentrates on giving you the tools and knowledge to manage your symptoms effectively in daily life, rather than immediately reaching for invasive procedures.

Practical self-care measures include:

• Dietary modification: Temporarily avoiding hard, chewy, or wide-opening foods (raw carrots, crusty bread, large sandwiches) to reduce joint loading
• Jaw rest: Avoiding unnecessary jaw movements such as wide yawning, prolonged singing, or resting your chin on your hand
• Heat and cold therapy: Moist heat applied to the masseter and temporalis muscles for 10–15 minutes can reduce muscle spasm; ice packs help manage acute inflammatory flare-ups
• Postural awareness: Correcting forward head posture, which places additional strain on the cervical-mandibular complex, is a commonly overlooked but clinically relevant strategy worth discussing with your clinician
• Stress management: Because psychological stress is a major driver of both bruxism and muscle hyperactivity, relaxation techniques, mindfulness, and cognitive behavioural approaches form an important adjunct to physical treatment

Occlusal splints: the evidence and the nuances

Occlusal splints — custom-fabricated intraoral devices worn over the teeth — are among the most widely prescribed TMD treatments globally. There are different splint types, each addressing various conditions: they may treat individuals with temporomandibular disorders and bruxism, assist with occlusal stabilisation, or reduce dentition wear.

The most evidence-supported type is the hard stabilisation splint (also called a flat-plane or centric stabilisation splint). Conservative management is the preferred first-line approach for most TMD cases, particularly those of myofascial or arthrogenous origin, and occlusal splints sit at the centre of that approach — custom-fitted devices that redistribute occlusal forces, reduce muscle hyperactivity, and decrease joint loading.

The mechanism works on several levels: splints set the jaw into a relaxed state, balance the occlusion, and support the TMJ, reducing strain on both the joint and surrounding muscles. By restoring neuromuscular balance, they help prevent premature tooth contact, which decreases pressure on the TMJ and alleviates muscle tension and joint pain.

That said, the evidence base is more nuanced than widespread clinical use might suggest. A 2024 Cochrane systematic review by Singh et al., examining 57 RCTs involving 2,846 participants, found that using an occlusal splint may reduce pain in muscles when chewing compared to no treatment — but the results are very uncertain, and there is little or no evidence of other benefits.

More importantly, there is no clear evidence that occlusal splints are superior to physiotherapy in treating TMDs; in long-term follow-up, they were equally effective as other therapies. The clinical implication is clear: splints are valuable tools, but not a standalone solution. Combining them with physiotherapy and behavioural strategies typically produces better outcomes than splints alone.

One critical distinction — explored fully in our guide on Occlusal Splints vs. Mandibular Advancement Splints for Bruxism: Choosing the Right Device — is that a standard occlusal splint is not appropriate for patients with co-existing obstructive sleep apnoea. If this applies to you, a mandibular advancement splint (MAS) that simultaneously addresses the airway is the clinically superior choice.

Splint selection at a glance

Tier 2: Jaw physiotherapy and exercise therapy

Physiotherapy is a cornerstone of evidence-based TMD management that is frequently underutilised by patients who receive only a splint and no active rehabilitation. If you've been given an appliance and little else, the evidence strongly supports adding physiotherapy to your care.

A 2024 narrative review confirmed that physiotherapy improves pain relief, range of motion, and overall jaw function in TMD patients. A 2025 systematic review of RCTs published between 2020 and 2025 found that physiotherapy — particularly manual therapy, therapeutic exercise, and laser therapy — was generally associated with reductions in pain and improvements in jaw mobility and function, providing short-term benefits in adults with TMD.

The highest-quality synthesis to date is an umbrella meta-meta-analysis by Arribas-Pascual et al. (Journal of Clinical Medicine, 2023), which pooled 31 systematic reviews and found moderate effects for manual therapy and therapeutic exercise, and large effects for low-level laser therapy on improving pain intensity and maximum mouth opening in patients with TMD.

What jaw physiotherapy involves

Therapeutic exercise protocols combined with manual therapy are the most commonly used methods for addressing TMDs and produce the best results across the analysed studies. A structured programme typically includes:

1. Manual therapy: Skilled hands-on mobilisation and manipulation of the TMJ and cervical spine by a trained physiotherapist, targeting joint mobility restrictions and myofascial trigger points
2. Therapeutic exercises: Controlled jaw opening and closing exercises, resisted movements, and coordination training to restore normal neuromuscular function
3. Cervical spine treatment: Because the TMJ and cervical spine are biomechanically coupled, physiotherapy at the cervical level contributes directly to improving your quality of daily life
4. Self-rehabilitation: All exercises performed independently by you, based on your practitioner's instructions — including self-massage and techniques aimed at correcting a deflected jaw opening, regularly supervised by a physiotherapist
5. Electrotherapy modalities: Ultrasound, TENS (transcutaneous electrical nerve stimulation), and low-level laser therapy as adjuncts to manual treatment

A multimodal approach combining splint therapy, physiotherapy, and patient counselling consistently outperforms any single modality. The combined use of manual therapy, occlusal splint, and counselling has produced the best results in reducing pain, depression, and anxiety — a meaningful outcome for overall wellbeing, not just jaw mechanics.

Tier 3: Pharmacological support

Medications don't cure TMD, but they play an important supporting role in managing acute pain and inflammation, enabling more effective engagement with physiotherapy and splint therapy.

Common pharmacological options include:

• NSAIDs (ibuprofen, naproxen): Reduce inflammatory pain, particularly useful in acute arthrogenous TMD flare-ups; short courses are preferred to avoid gastrointestinal side effects
• Muscle relaxants (diazepam, cyclobenzaprine): May reduce nocturnal muscle hyperactivity in bruxism-driven TMD, though long-term use is generally avoided due to dependency risk
• Tricyclic antidepressants (amitriptyline at low dose): Used for chronic myofascial pain with a central sensitisation component
• Topical analgesics: Diclofenac gel applied over the masseter and TMJ region can provide localised relief with minimal systemic absorption

The evidence related to pharmacological treatment varies because individual studies, systematic reviews, and meta-analyses lack consistency in evaluating specific agents. Some systematic reviews have found significant benefit from analgesics, muscle relaxants, and anti-inflammatory medications versus placebo; others have not. Your clinician will discuss the most appropriate options for your specific situation.

Tier 4: Botulinum toxin (Botox) for masseter pain and bruxism

Botulinum toxin Type A (BTX-A) has become a clinically significant option for patients with refractory myogenous TMD and bruxism-driven jaw pain who haven't responded adequately to conservative measures. It's an approach our experienced clinicians at Smile Solutions can discuss with you in the context of your broader treatment plan.

BTX-A blocks neuromuscular transmission, causing muscle relaxation and decreased muscle contractions. When injected into the masseter, temporalis, and medial pterygoid muscles, it reduces the forceful hyperactivity that drives both bruxism-related tooth damage and myofascial pain.

What the evidence shows

A 2024 systematic review and meta-analysis by Li et al. (Journal of Oral Rehabilitation), encompassing 15 RCTs and 504 participants, found that BTX-A was significantly more effective than placebo in reducing pain intensity at 1 month (MD −1.92 [−2.87, −0.98], p < .0001) and 6 months (MD −2.08 [−3.19 to −0.98]; p = .0002).

The review also found that a higher dose of BTX-A produced greater pain reduction at 6 months. Injections at the masseter, temporalis, and pterygoid muscles together were linked to greater pain reduction than injections at the masseter and temporalis alone.

For bruxism specifically, a 2024 systematic review of nine RCTs (Naji et al., Dentistry Journal, MDPI) found significant reductions in mean pain scores — from 7.1 to 0.2 at 6 months and 1 year post-treatment in one study — and a notable decrease in bruxism events from 4.97/h to 1.70/h in the BTX-A group in another. Improvements in jaw stiffness and total sleep time were also observed.

A Bayesian network analysis published in the Journal of Dental Sciences (2024) concluded that BTX-A significantly relieves bruxism pain for 6 months after injection, with therapeutic efficacy higher than oral splinting.

Safety and practical considerations

There was no significant difference in adverse effects between BTX-A and placebo. Overall, BTX-A holds promise in reducing muscular TMD pain and alleviating pain-related disability without causing significant adverse effects. Side effects were generally mild and transient — injection site pain in 20% of participants in one study, and temporary cosmetic changes in smile in 15.4% of patients in another. Your clinician will walk you through these considerations as part of a thorough informed consent discussion.

BTX-A is not a cure for TMD. Effects typically last 3–6 months, and repeat injections are required for sustained benefit. It's best understood as a bridge therapy — reducing muscular load sufficiently to allow physiotherapy and behavioural interventions to take effect. It is also not appropriate for arthrogenous (joint-structural) TMD, where the primary pathology lies within the joint itself rather than in the surrounding muscles.

Tier 5: Minimally invasive joint interventions

When conservative and pharmacological measures fail to provide adequate relief — particularly in arthrogenous TMD with confirmed internal derangement, adhesions, or inflammatory joint disease — minimally invasive procedural interventions are considered.

Arthrocentesis

Arthrocentesis is performed under local anaesthesia to flush out the superior space of the TMJ. It aims to reduce intra-articular pressure and control pain. Fluids used for joint space lavage include normal saline, steroids, botulinum toxin, hyaluronic acid (HA), or anti-inflammatory agents. The procedure encompasses three key steps: separating the joint constituents, removing inflammation, and eliminating intra-articular effusion.

Whilst physiotherapy, behavioural therapy, occlusal splints, and lasers remain the first-line treatment for TMDs, arthrocentesis has emerged as an effective alternative to surgical intervention. A 2023 meta-analysis by Hu et al. found that at 1 month and 6 months (but not at 3 months), arthrocentesis used as a first-line treatment significantly reduced pain scores compared to conservative therapies.

Intra-articular injections

Following arthrocentesis, or as standalone procedures, various agents can be injected into the TMJ space:

• Hyaluronic acid (HA): A linear polysaccharide naturally present in the synovium, used for its anti-inflammatory and lubricating properties. It also reduces mechanical wear, supports cartilage tissue repair, and stimulates production of endogenous acids by synovial cells.
• Corticosteroids: Useful for acute inflammatory TMD, though long-term use is limited by potential cartilage effects
• Platelet-rich plasma (PRP): An emerging regenerative option, though evidence remains preliminary

The use of injections — either after arthrocentesis or in combination with other modalities — has resulted in better outcomes, reflecting an evolving trend towards personalised, multimodal treatment approaches that our multidisciplinary team at Smile Solutions is well-positioned to deliver.

It should be noted that the evidence for intra-articular injections remains contested. Some analyses have found that intra-articular pharmacological injections of corticosteroids, hyaluronic acid, and platelet-rich plasma did not produce any significant improvement in TMJ pain and functional outcomes when compared with placebo injections — which underscores the importance of careful patient selection and thorough clinical reasoning before proceeding.

When are these interventions warranted?

Arthrocentesis and joint injections are typically considered when:

• Confirmed disc displacement without reduction (closed lock) has not responded to conservative management over 3–6 months
• Significant intra-articular inflammation is present on MRI
• Jaw opening is severely restricted, affecting nutrition and quality of life
• Conservative options have been genuinely optimised

These procedures are performed by oral and maxillofacial surgeons or specialist TMD clinicians, and referral from a dental TMD specialist is the standard pathway.

The conservative-first, cause-targeted framework

The evidence converges on a clear clinical philosophy: treatment modalities include education, self-care strategies, simple analgesics, dental occlusal splints, physiotherapy, and even acupuncture — however, systematic reviews have yet to identify a universally superior treatment modality.

This absence of a single "best" treatment reflects TMD's heterogeneity, not a weakness of the field. The clinically appropriate response is a tiered, cause-targeted approach that your clinician at Smile Solutions will tailor specifically to you:

1. Identify the subtype first (myogenous, arthrogenous, or mixed) using validated diagnostic criteria (DC/TMD protocol)
2. Start conservatively with patient education, self-care, and splint therapy appropriate to your diagnosis
3. Add physiotherapy as an active rehabilitation component, particularly for myogenous TMD
4. Consider BTX-A for refractory muscular TMD or bruxism-driven pain not responding to conservative measures
5. Escalate to joint interventions only when conservative measures have been genuinely optimised and joint pathology is confirmed

If you have co-existing bruxism and snoring or suspected obstructive sleep apnoea, airway assessment is essential before splint selection — as described in our guide on The TMD–Bruxism–Sleep Apnoea Connection.

Key takeaways

• First-line TMD treatment includes physiotherapy, behavioural therapy, occlusal splints, and lasers — not any single modality in isolation.
• Occlusal splints are not superior to physiotherapy in long-term follow-up; they were equally effective as other therapies, which makes combination treatment the rational default.
• BTX-A injections into the masseter and temporalis muscles are significantly more effective than placebo for muscular TMD pain at both 1 and 6 months, with higher doses (60–100 U bilaterally across the masseter, temporal, and pterygoid muscles) producing greater pain reduction without significant adverse events.
• If pain persists despite initial conservative treatments, more invasive methods such as injections and arthrocentesis should be considered — but only after conservative options have been genuinely optimised.
• Comprehensive TMD assessment based on the biopsychosocial health model, carried out by a specialised multidisciplinary team spanning dentistry, pharmacology, physiotherapy, psychology, and surgery, is the most appropriate framework for both treatment and research.

Conclusion

TMD treatment in Melbourne — and globally — works best when it is matched precisely to the underlying cause, delivered in a logical sequence from least to most invasive, and monitored with objective outcome measures. The spectrum from self-care and occlusal splints through to jaw physiotherapy, Botox, and arthrocentesis is not a menu of interchangeable options: it is a clinical hierarchy, and navigating it well requires both accurate diagnosis and genuine multidisciplinary expertise.

For patients whose TMD is entangled with bruxism and obstructive sleep apnoea — a triad more common than most people realise — the treatment picture becomes even more complex. A mandibular advancement splint may simultaneously address all three conditions; a standard occlusal splint may inadvertently worsen one of them. Understanding these distinctions is what separates a comprehensive TMD assessment from a simple appliance prescription, and it is the kind of care our experienced specialists at Smile Solutions are committed to delivering.

To explore the diagnostic process in detail, see our guide on How TMD, Bruxism, and Sleep Apnoea Are Diagnosed. For a closer look at specific device options, visit Mandibular Advancement Splints Explained and Occlusal Splints vs. Mandibular Advancement Splints for Bruxism: Choosing the Right Device.

Smile Solutions has been providing comprehensive dental care from Melbourne's CBD since 1993. Located at the Manchester Unity Building, Level 1 and 10, 220 Collins Street, Smile Solutions brings together 60+ clinicians — including 25+ board-registered specialists — who have cared for over 250,000 patients. No referral is required to book a specialist appointment. If you're ready to take the next step towards personalised TMD care, call 13 13 96 or visit smilesolutions.com.au to arrange your TMD and sleep treatment consultation today.

References

• Li, K., Tan, K., Yacovellia, A., & Bi, W.G. "Effect of botulinum toxin type A on muscular temporomandibular disorder: a systematic review and meta-analysis of randomized controlled trials." Journal of Oral Rehabilitation, 2024. https://doi.org/10.1111/joor.13648

• Naji, A. et al. (Saini et al.). "The effectiveness of botulinum toxin for temporomandibular disorders: A systematic review and meta-analysis." PLOS ONE, March 2024. https://doi.org/10.1371/journal.pone.0300157

• Alhaddad, M. et al. "Efficacy and Safety of Botulinum Toxin in the Management of Temporomandibular Symptoms Associated with Sleep Bruxism: A Systematic Review." Dentistry Journal (MDPI), 12(6):156, 2024. https://doi.org/10.3390/dj12060156

• Singh, B.P. et al. "Occlusal interventions for managing temporomandibular disorders." Cochrane Database of Systematic Reviews, 2024. https://doi.org/10.1002/14651858.CD012850.pub2

• Gupta, A.K. et al. "Centric stabilization occlusal splints vs. other conservative therapies in the management of temporomandibular disorders: a systematic review and meta-analysis." The Saudi Dental Journal / Springer Nature, 2025. https://doi.org/10.1007/s44445-025-00052-9

• Arribas-Pascual, M. et al. "Effects of Physiotherapy on Pain and Mouth Opening in Temporomandibular Disorders: An Umbrella and Mapping Systematic Review with Meta-Meta-Analysis." Journal of Clinical Medicine, 12(3):788, 2023. https://doi.org/10.3390/jcm12030788

• Ortega-Santiago, R. et al. "Temporomandibular Joint Dysfunctions: A Systematic Review of Treatment Approaches." Journal of Clinical Medicine, 12(12):4156, 2023. https://doi.org/10.3390/jcm12124156

• Sood, A. et al. "Effectiveness of non-invasive physiotherapy techniques in managing chronic temporomandibular disorder pain: a narrative review." Journal of Oral and Maxillofacial Anesthesia, 2024. https://joma.amegroups.org/article/view/7122/html

• Manafikhi, M. et al. "Systematic Review: Injectable interventions for TMJ pain management." Journal of Clinical and Pharmaceutical Research, 2024. https://jcpres.com/storage/upload/pdfs/1709625096-en.pdf

• Agency for Healthcare Research and Quality (AHRQ). "Topic Brief: Temporomandibular Disorder Treatment Guidelines." AHRQ Effective Health Care Program, February 2023. https://effectivehealthcare.ahrq.gov/sites/default/files/nt_docs/1029-temporomandibular-dysfunction-topic-brief.pdf

• Kuzmanovic Pficer, J. et al. "Occlusal stabilization splint for patients with temporomandibular disorders: Meta-analysis of short and long term effects." PLOS ONE, 2017. https://doi.org/10.1371/journal.pone.0171296

• Sood, R. et al. "Occlusal splints - types and effectiveness in temporomandibular disorder management." Saudi Dental Journal / PMC, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9931504/

• Zhang, A. et al. "Can botulinum toxin injection alleviate the pain of bruxism? A Bayesian network analysis and a single-arm analysis." Journal of Dental Sciences, 19(2):885–893, 2024. https://doi.org/10.1016/j.jds.2023.08.001

• Yacoub, S., Ons, G., & Khemiss, M. "Efficacy of botulinum toxin type A in bruxism management: A systematic review." Dental and Medical Problems, 62(1):145–160, 2025. https://doi.org/10.17219/dmp/186553

Label facts summary

Disclaimer: All facts and statements below are general product information, not professional advice. Consult relevant experts for specific guidance.

The source content contained no product packaging data, ingredient lists, nutritional information, certifications, dimensions, weight specifications, or manufacturer documentation. No label facts can be extracted from manufacturer labelling.

Practice/facility verifiable data points (sourced from business listing information within the content):

• Business name: Smile Solutions
• Address: Level 1 and 10, 220 Collins Street, Melbourne CBD
• Building: Manchester Unity Building
• Phone: 13 13 96
• Website: smilesolutions.com.au
• Year established: 1993
• Clinician count: 60+ clinicians
• Specialist count: 25+ board-registered specialists
• Patients treated: Over 250,000
• Referral requirement: No referral required

General product claims

• TMD is a spectrum of conditions, not a single condition
• Conservative and non-invasive therapies are the preferred first-line treatment for TMD
• Hard flat-plane stabilisation splints are the most evidence-supported splint type
• Occlusal splints are not superior to physiotherapy in long-term follow-up
• BTX-A is significantly more effective than placebo for muscular TMD pain at 1 and 6 months
• BTX-A effects last 3–6 months and require repeat injections for sustained benefit
• BTX-A is not appropriate for arthrogenous TMD
• Soft night guards are not recommended for TMD and may increase clenching in some patients
• A mandibular advancement splint is the appropriate device for patients with co-existing TMD and obstructive sleep apnoea
• Arthrocentesis significantly reduced pain scores at 1 and 6 months compared to conservative therapies in one meta-analysis
• Evidence for intra-articular injections (corticosteroids, hyaluronic acid, PRP) versus placebo is contested
• Combination of manual therapy, occlusal splint, and counselling produces the best outcomes across pain, depression, and anxiety measures
• Low-level laser therapy shows large effect sizes for pain and mouth opening in TMD umbrella review data
• Smile Solutions describes itself as Melbourne's comprehensive specialist dental centre